Rapamycin Derivatives for Solid Tumor Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments for solid tumors often fail to induce regression or stabilization, and there is a need for more effective methods to inhibit tumor growth, invasiveness, and metastatic spread, especially in cases where standard anticancer compounds are ineffective.
Innovation Solution
Administration of therapeutically effective amounts of rapamycin or its derivatives, such as Compound A, to treat solid tumors, inhibit tumor growth, induce regression, and prevent metastasis by targeting antiproliferative and anti-angiogenic pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard anticancer compounds are used to treat solid tumors, then treatment is provided, but the treatment often fails to induce regression or stabilization
Solution Approach 1:
The patent changes the therapeutic parameter by introducing rapamycin and its derivatives (specifically compounds of formula I with R1=CH3 or C3-6alkynyl, R2=H or —CH2—CH2OH, and X=═O, (H,H) or (H,OH)) as a new active ingredient with different mechanism of action (mTOR inhibition) compared to standard chemotherapeutics, thereby achieving treatment effectiveness in cases resistant to conventional treatments
2Reliability
If rapamycin derivatives are administered to inhibit tumor growth, then antiproliferative activity is achieved, but the mechanism involves complex mTOR pathway inhibition
Solution Approach 1:
The patent uses mTOR (mammalian target of rapamycin) as an intermediary target in the signaling pathway. Rapamycin and its derivatives bind to FKBP-12 (FK506 binding protein) to form a complex that then inhibits mTOR, thereby indirectly blocking the PI3K/Akt/mTOR signaling pathway and achieving tumor growth inhibition without directly targeting multiple complex pathways
3Reliability
If combination therapy with chemotherapeutic agents is used, then synergistic effects may be achieved, but treatment complexity increases
Solution Approach 1:
The patent merges rapamycin/derivative therapy with conventional chemotherapeutic agents into a combination regimen. This combination exploits the different mechanisms of action (mTOR inhibition vs. direct cytotoxicity) to achieve synergistic therapeutic effects, where the rapamycin component sensitizes tumor cells to chemotherapy while the chemotherapy eliminates rapidly dividing cells
Data Source
AI summary
Rapamycin derivatives have interesting effects in the treatment of solid tumors, optionally in combination with a chemotherapeutic agent.